These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27234586)

  • 1. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine.
    Bhutia YD; Babu E; Ganapathy V
    Biochem J; 2016 Jun; 473(11):1503-6. PubMed ID: 27234586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
    Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
    Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of antineoplastic activity of lonidamine.
    Nath K; Guo L; Nancolas B; Nelson DS; Shestov AA; Lee SC; Roman J; Zhou R; Leeper DB; Halestrap AP; Blair IA; Glickson JD
    Biochim Biophys Acta; 2016 Dec; 1866(2):151-162. PubMed ID: 27497601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000.
    Kaplan O
    Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272
    [No Abstract]   [Full Text] [Related]  

  • 5. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment.
    Miccoli L; Poirson-Bichat F; Sureau F; Bras Gonçalves R; Bourgeois Y; Dutrillaux B; Poupon MF; Oudard S
    J Natl Cancer Inst; 1998 Sep; 90(18):1400-6. PubMed ID: 9747871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Targeting the gene of glucose metabolism for the treatment of advanced gliomas].
    Oudard S; Miccoli L; Dutrillaux B; Poupon MF
    Bull Cancer; 1998 Jul; 85(7):622-6. PubMed ID: 9752269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mitochondrial voltage-dependent anion channel 1 in tumor cells.
    Shoshan-Barmatz V; Ben-Hail D; Admoni L; Krelin Y; Tripathi SS
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2547-75. PubMed ID: 25448878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
    Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
    Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
    Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
    Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
    Silvestrini B; Hahn GM; Cioli V; De Martino C
    Br J Cancer; 1983 Feb; 47(2):221-31. PubMed ID: 6824568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lonidamine on the aerobic glycolysis of normal and phytohemagglutinin-stimulated human peripheral blood lymphocytes.
    Nista A; De Martino C; Malorni W; Marcante ML; Silvestrini B; Floridi A
    Exp Mol Pathol; 1985 Apr; 42(2):194-205. PubMed ID: 3156759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lonidamine in malignant brain tumors.
    Schiffer D; Sales S; Soffietti R
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):38-41. PubMed ID: 2031197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on therapeutic opportunities offered by cancer glycolytic metabolism.
    Granchi C; Fancelli D; Minutolo F
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4915-25. PubMed ID: 25288186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lonidamine, a new approach to cancer therapy.
    Caputo A; Silvestrini B
    Oncology; 1984; 41 Suppl 1():2-6. PubMed ID: 6371644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
    Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
    Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
    Cervantes-Madrid D; Romero Y; Dueñas-González A
    Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lonidamine in metastatic breast cancer.
    Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of Lonidamine in patients with advanced malignancy.
    Evans WK; Shepherd FA; Mullis B
    Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
    Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
    Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological effects of lonidamine on two human-tumor cell culture lines.
    Szekely JG; Lobreau AU; Delaney S; Raaphorst GP; Feeley M
    Scanning Microsc; 1989 Jun; 3(2):681-91; discussion 691-3. PubMed ID: 2814409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.